Press Releases

iXCells Biotechnologies a provider of cell products and drug discovery services to the worldwide academic, biotech and pharmaceutical communities, today announced expansion of its CRISPR-Cas9 product and custom services offering, with special focus on induced pluripotent stem cell (“iPSC”) derived cell models. iXCells’ team of scientific experts in gene editing have already introduced several iPSC derived human motor neuron disease models that include gene mutation

The specialty chemicals company LANXESS has achieved its forecast earnings for the first quarter of 2023: EBITDA pre exceptionals came to EUR 189 million, within the range of EUR 180 million to EUR 220 million forecast in March. Compared with the previous year’s figure of 262 million euros,  earnings thus declined by 27.9 percent. Sales remained almost stable. They amounted to EUR 1.899 billion, down only 1.7 percent from the previous year’s figure of EUR 1.931 million.

Specialty chemicals company LANXESS has grouped together 16 new ion exchange resins and absorbents for the pharmaceutical and bioprocessing industries under its trusted umbrella brand Lewatit. They are used in various pharmaceutical and bioprocessing applications to separate and purify biomolecules. Applications of these end products range from food and animal feeds to active pharmaceutical ingredients (APIs) that are used in medicinal products. “Typically, our products suppor

Today, the U.S. Food and Drug Administration approved Veozah, an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain's regulation of body temperature. "Hot flashes as a result of

Actinium Pharmaceuticals, Inc. a leader in the development of targeted radiotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming European Hematology Association 2023 Congress  which will be held in Frankfurt, Germany June 8-11, 2023.  The abstract includes data from Actinium's SIERRA controlled phase 3 study comparing the efficacy of Iomab-B based conditioning, a first-in-class targeted radiotherapy, versus physician's choice of

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. Ken Guo, a co-founder of Vector Biolabs, said, “The purpose of the expansion was two-fold – it doubles our capacity, allowing us to extend our custom AAV and adenovirus production services to a wider audience in gene delivery, gene editing, and cell therapy applications, and it adds cleanroom space and anal

Genesis Drug Discovery and Development , Contract Research Organization  arm and member of Genesis Global Group, announced today that it has acquired JSS Medical Research. With corporate headquarters in Montreal, Canada, and regional offices in Bogotá, Columbia, Faridabad, India, and Warsaw, Poland, JSS Medical Research provides pre- and post-approval clinical development services to support pharmaceutical, biotechnology, nutraceutical and medical device companies worldwide.

Boehringer Ingelheim and Zealand Pharma A/S today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint. These results including an analysis of the actual maintenance dose indicating

Rocket Pharmaceuticals, Inc. a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A601, an AAV.rh74-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy due to plakophilin 2 pathogenic variants (PKP2

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), continues to drive the expansion of capacities and services for the provision of clinical trial materials: With the implementation of additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria, the company is responding to increasing market demand. By the end of 2021, Vetter’s production in Rankweil was up and running, and 17 customer pr